WCLC 2021 | NICE approval: brigatinib in ALK NSCLC
Raffaele Califano, MD, of The Christie NHS Foundation Trust, Manchester, UK, discusses the recent NICE approval of brigatinib for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) who have not been previously treated with an ALK inhibitor. This approval is based on results reported from the ALTA-1L study (NCT02737501). Dr Califano reports that brigatinib has high efficacy on brain metastases, which are often a challenge to treat in ALK-positive NSCLC, and shows great promise for the treatment of patients with CNS disease. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Honoraria and consultancy fees: AstraZeneca, Boeringher Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, Bristol Myers Squibb, Takeda, Novartis
Grants paid to Institution for conduct of clinical trials or contracted research: Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, BMS, Abbvie, Takeda, Novartis
Stock Ownership: The Christie Private Care
Non-remunerated activities: Principal investigator for trials with Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, BMS, Abbvie, Takeda, Novartis
Other non remunerated membership: ESMO, EORTC
